Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Annals of Oncology

• Publication date

  2016-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ANNONC/MDW370.04
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Same mutation, different fates: The Yin-Yang of BRAF-driven therapeutic responses in melanoma and colorectal cancer.

  2025cites this paper
• Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments

  2023cites this paper
• Liquid Biopsy in Advanced Colorectal Cancer: Clinical Applications of Different Analytes

  2023cites this paper
• Selection of Oral Therapeutics in China for the Treatment of Colorectal Cancer

  2021cites this paper
• Precision oncology in metastatic colorectal cancer — from biology to medicine

  2021cites this paper
• Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.

  2021cites this paper
• Cisplatin inhibits the proliferation of Saos-2 osteosarcoma cells via the miR-376c/TGFA pathway

  2020cites this paper
• Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers

  2020cites this paper
• Comprehensive review of targeted therapy for colorectal cancer

  2020cites this paper
• Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements

  2020cites this paper
• Landscape of Current Targeted Therapies for Advanced Colorectal Cancer

  2020cites this paper
• BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy

  2020cites this paper
• The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation

  2019cites this paper
• a detailed clinical, pathological and molecular characterization

  2019cites this paper
• Treatment sequencing in metastatic colorectal cancer.

  2019cites this paper
• First‐line therapy for metastatic colorectal cancer: Current perspectives and future directions

  2019cites this paper
• BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights

  2019cites this paper
• Circulating Tumour Cells, Circulating Tumour DNA and Circulating Tumour miRNA in Blood Assays in the Different Steps of Colorectal Cancer Management, a Review of the Evidence in 2019

  2019cites this paper
• BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study

  2019cites this paper
• BRAF Mutation and Its Importance in Colorectal Cancer

  2019cites this paper
• Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization

  2019cites this paper
• Chemotherapy, Still an Option in the Twenty-First Century in Metastatic Colorectal Cancer?

  2019cites this paper
• a detailed clinical, pathological and molecular characterization

  2019cites this paper
• Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors

  2018cites this paper
• Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.

  2018cites this paper
• Emerging treatment options for BRAF-mutant colorectal cancer

  2018cites this paper
• Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives

  2018cites this paper
• Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.

  2018cites this paper
• BRAF-mutant colorectal cancer, a different breed evolving

  2018cites this paper
• Monitoring resistance through liquid biopsy.

  2018cites this paper
• How should BRAF V600E-mutated colorectal cancer be treated?

  2018cites this paper
• Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models

  2018influential citation
• Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer

  2018cites this paper
• BRAF — a new therapeutic target in colorectal cancer

  2018cites this paper
• Nivolumab in patients with metastatic DNA mismatch repair deficient/microsatellite instability–high colorectal cancer (CheckMate 142): results of an open-label, multicentre, phase 2 study

  2018cites this paper
• resistance through liquid biopsy

  2018cites this paper
• Chemotherapies and future directions in metastatic colorectal cancer

  2017cites this paper
• Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches.

  2017influential citation
• European Society for Medical Oncology Copenhagen update: potential practice-changing findings

  2017cites this paper
• Molecular Stratification of Colorectal Cancer: Moving from the Laboratory to Clinical Practice

  2017cites this paper
• Biomarker-driven and molecular targeted therapies for colorectal cancers.

  2017cites this paper
• Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy

  2017cites this paper
• Targeted Therapy and the Use of Molecular Profiling in Metastatic Colorectal Cancer

  2017influential citation
• Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications.

  2017cites this paper
• Impact of Metastasectomy in the Multimodality Approach for BRAF V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience.

  2017cites this paper
• BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?

  2017cites this paper
• Current and future biomarkers in colorectal cancer

  2017cites this paper
• Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies.

  2017cites this paper
• Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer

  2017cites this paper
• Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

  2017cites this paper
• BRAF +/- MEK inhibition in patients (pts) with BRAF-mutant (mut) metastatic colorectal cancer (mCRC): The Sarah Cannon Research Institute UK’s experience.

  2017cites this paper
• Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study

  2017cites this paper
• Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives

  2017cites this paper
• Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies.

  2017cites this paper
• BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives

  2017cites this paper
• [What biomarkers for the future? The point of view of the residents in oncology after the ESMO 2016 Congress].

  2017cites this paper
• World Journal of Gastroenterology

  year unknowncites this paper